OriCell Therapeutics gives full play to the three independently-developed technology platforms (three benefits in one) and sets out to break through the efficacy and cost bottlenecks in CAR T-cell therapy for solid tumors:

Target screening as the first benefit: The Ori^®Ab platform not only offers high-quality and highly synergistic targets for the CAR-T products but also screens out the appropriate ones to develop candidate antibody drugs. These products are authorized and licensed or are developed in a collaborative manner to create values for the company;

Innovative structure as the second benefit: The Ori^®CAR platform with an innovative structure can expand the memory T-cells at a rate that is several-fold higher so that the cell products can effectively resist the immunosuppressive tumor microenvironment;

Processes as the third benefit: Ori^®TIL enjoys a complete set of mature and universal processes for the cell culture and expansion platform to ensure standardized and large-scale production of the cellular therapy products and reduce inter-batch differences; this benefit can help solve the problem of lacking specific targets for solid tumor treatment;